 |
63 Diseases |  |
25 Trials |
|
25 Trials |  |
493 News |  |
| 1234567» |
- || dexamethasone / Generic mfg., fosaprepitant / Generic mfg.
Retrospective data, Review, Journal: Fosaprepitant as combination therapy to prevent chemotherapy-induced vomiting in children: a meta-analysis. (Pubmed Central) - Feb 7, 2025
The subgroup analysis of salvage treatment proportion revealed that the need for rescue medication was higher for patients in the control than fosaprepitan regimens [RR = 0.20, 95%CI = 0.08-0.54, P = 0.001] There was no difference in the incidence of adverse drug reaction between two groups [RR = 0.95, 95%CI = 0.75-1.19, P = 0.66]. Fosaprepitant in combination with 5-HT3RA (with or without dexamethasone) has the same safety and more effective in preventing chemotherapy-induced vomiting than 5-HT3RA with or without dexamethasone.
- | fosaprepitant / Generic mfg.
Journal, CINV: Prospective clinical evidence from over 1,000 pan-cancer patients: a complement to fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting. (Pubmed Central) - Jan 15, 2025
Single-dose fosaprepitant has shown good performance in real-world clinical practice. This study is the first to prospectively evaluate the efficacy and safety of fosaprepitant for the prevention of CINV in a real-world clinical setting and may be a good complement to the clinical data.
- | Journal: Mitigating the Risk of QTc Prolongation When Using Haloperidol for Acute Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents and Young Adults. (Pubmed Central) - Jan 12, 2025
We recommend vigilant EKG monitoring, particularly before initiating and throughout haloperidol treatment. If the patient presents with an increased risk of QTc prolongation, consider using topical capsaicin, lorazepam, aprepitant/fosaprepitant, and olanzapine as alternatives.
- pegcantratinib (SNA-120) / Sienna, Rituxan (rituximab) / Roche
Lymphoproliferative Disorder Of The Vulva - A Rare Case Report (Poster area) - Jan 4, 2025 - Abstract #ESGO2025ESGO_813;
Our patient achieved complete remission after 2 cycles of R-COP regimen. Conclusion Primary non-Hodgkin's malignant lymphoma of the vulva remains undiagnosed due to its uncommon presentation; thus gynecologic oncologists, and onco-pathologists should be aware of this clinical entity.
- | fosaprepitant / Generic mfg.
New P2/3 trial: BARF RCT: Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (clinicaltrials.gov) - Dec 18, 2024
P2/3, N=212, Not yet recruiting, Sponsor: Montefiore Medical Center
- | Bridion (sugammadex) / Merck (MSD)
Journal: Anesthesia Providers' Knowledge of Medication Interference with Hormonal Contraception: A Multisite Survey. (Pubmed Central) - Dec 16, 2024
To facilitate SDM, it is imperative that providers discuss alternative medications and the potential need for additional contraception methods after drug administration and communicate the risks with patients preoperatively to enable informed and SDM. The patient's preferences should be accounted for, especially if they are unwilling or unable to use an alternative contraceptive for 7 to 30 days, thereby avoiding the complexities and burdens of altering birth control methods.
- || fosaprepitant / Generic mfg.
P4 data, Journal, CINV: Safety and Tolerability of a 3-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients: Results of an Open-Label, Single-Arm Phase 4 Trial. (Pubmed Central) - Dec 10, 2024
No deaths were reported. The 3-day IV fosaprepitant regimen for the prevention of CINV was generally well tolerated in pediatric patients receiving emetogenic chemotherapy.
- ||| Varubi (rolapitant oral) / TerSera Therap, GSK, HR20013 / Jiangsu Hengrui Pharma, Varubi IV (rolapitant IV) / TerSera Therap, GSK
P3 data, Journal, CINV: Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. (Pubmed Central) - Dec 2, 2024
The 3-day IV fosaprepitant regimen for the prevention of CINV was generally well tolerated in pediatric patients receiving emetogenic chemotherapy. HR20013 + DEX was noninferior to FAPR + PALO + DEX for preventing HEC-CINV and well tolerated, with the potential to reduce the impact of CINV on daily life.
- | fosaprepitant / Generic mfg.
Journal: Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology. (Pubmed Central) - Oct 27, 2024
HR20013 + DEX was noninferior to FAPR + PALO + DEX for preventing HEC-CINV and well tolerated, with the potential to reduce the impact of CINV on daily life. This study provides updated guidelines for the prevention and treatment of EV, which can be used to help health care providers and patients and their families practice better EV management.
- | Trial completion, Trial completion date: Proton-PANC: Study of Proton Therapy in Adjuvant Pancreatic Cancer (clinicaltrials.gov) - Oct 23, 2024
P1, N=9, Completed, Sponsor: Georgetown University
This study provides updated guidelines for the prevention and treatment of EV, which can be used to help health care providers and patients and their families practice better EV management. Recruiting --> Completed | Trial completion date: Dec 2021 --> Nov 2023
- | fosaprepitant / Generic mfg.
Retrospective data, Journal: Incidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study. (Pubmed Central) - Oct 9, 2024
EBMT has a high incidence of PONV during anesthesia recovery. Administration of a NK-1 antagonist as part of a multiagent PONV prophylaxis regimen dramatically reduces risk for this common adverse event.
- Cyramza (ramucirumab) / Eli Lilly
DESENSITIZATION TO RAMUCIRUMAB IN SIGNET-CELL GASTRIC ADENOCARCINOMA (Monitor 1; Hall A) - Sep 29, 2024 - Abstract #ACAAI2024ACAAI_690;
After anaphylaxis management with epinephrine and hydrocortisone a desensitization protocol (3-bag, 12-steps) was proposed and performed successfully with its proper premedication (dexamethasone, diphenhydramine, fosaprepitant and palonosetron) every 3 weeks without HSR for 4 cycles...Table 1. 3-Bags, 12-Steps Desensitization protocol to Ramucirumab.
- | Trial completion, Surgery, Machine learning: A Machine Learning Prediction Model for Delayed CIPONV (clinicaltrials.gov) - Sep 26, 2024
P=N/A, N=1154, Completed, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
3-Bags, 12-Steps Desensitization protocol to Ramucirumab. Recruiting --> Completed
- | Vyloy (zolbetuximab) / Astellas
Journal: Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets. (Pubmed Central) - Sep 23, 2024
Fosaprepitant showed suppressive effects on emesis, and use of dexamethasone or concomitant use of fosaprepitant with other antiemetics tended to alleviate gastric tissue damage. The onset of emesis in humans receiving zolbetuximab may be associated with damage in the gastric mucosa, and antiemetics may mitigate gastrointestinal adverse events.
- | fosaprepitant / Generic mfg.
New trial, Real-world evidence, Real-world: A real-world study on the safety and effectiveness of aprepitant injection and fosaprepitant dimeglumine for injection in preventing chemotherapy-related nausea and vomiting (CINV) in cancer patients (EUDRACT) - Sep 20, 2024
P=N/A, N=2000, Not yet recruiting, Sponsor: Shanghai General Hospital; Shanghai General Hospital
- | fosaprepitant / Generic mfg.
New P4 trial, Surgery: The Effect of Fosaprepitant on Postoperative Delirium and Sleep Quality in Elderly Gynecological Laparoscopic Surgery Patients: A Prospective Randomized Controlled Study (EUDRACT) - Sep 20, 2024
P4, N=310, Not yet recruiting, Sponsor: Obstetrics and Gynecology Hospital of Fudan University; Obstetrics and Gynecology Hospital of Fudan University
- | fosaprepitant / Generic mfg.
Enrollment open: Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov) - Sep 19, 2024
P2/3, N=250, Recruiting, Sponsor: Montefiore Medical Center
The onset of emesis in humans receiving zolbetuximab may be associated with damage in the gastric mucosa, and antiemetics may mitigate gastrointestinal adverse events. Not yet recruiting --> Recruiting
- | New P3 trial: FONDO-LOW: Olanzapine 2.5 Vs 5 Mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan (clinicaltrials.gov) - Sep 19, 2024
P3, N=172, Not yet recruiting, Sponsor: Augusta University
- olanzapine / Generic mfg.
The efficacy and safety of mirtazapine vs olanzapine in preventing chemotherapy induced nausea and vomiting in combination with the triplet regimen in patients receiving highly emetogenic chemotherapy: An open label, prospective, randomized control study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_889;
Proportion of patients with nausea, vomiting and need of rescue medication during acute, delayed and overall period in both the study groups will be analyzed. Table: 593TiP Treatment arms ARM Drug Days ARM A (FDP-M) INJ FOSAPREPITANT 150mg IV Day1 INJ DEXAMETHASONE 8-12mg IV followed by Day1 TAB DEXAMETHASONE 4mg BD Day 1-4 INJ PALONOSETRON 0.25mg IV Day 1 TAB MIRTAZAPINE 15mg OD Day 1-4 ARM B (FDP-O) INJ FOSAPREPITANT 150mg IV Day1 INJ DEXAMETHASONE 8-12mg IV followed by Day1 TAB DEXAMETHASONE 4mg BD Day 1-4 INJ PALONOSETRON 0.25mg IV Day 1 TAB OLANZAPINE 5mg OD Day 1-4 .
- Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, netupitant (Ro 67-3189) / Helsinn, Otsuka
Comparison of efficacy of single agent netupitant plus palonosetron (NEPA) vs fosaprepitant in prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving high dose chemotherapy for auto-SCT In a tertiary care center from South India (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_880;
As part of conditioning regimen, high dose melphalan and BEAM regimen were used in 31 and 9 patients respectively...The overall complete response (CR-O) was also higher in NEPA arm (77.8 % vs 60%). Conclusions Single agent oral NEPA is more effective in preventing CINV in acute, delayed, overall phases in patients receiving high dose chemotherapy as conditioning regimen for Auto-SCT.
- || fosaprepitant / Generic mfg.
Clinical, Journal: Comparing Injection Site Reactions of Aprepitant and Fosaprepitant in Gynecologic Cancer Chemotherapy. (Pubmed Central) - Aug 27, 2024
Conclusions Single agent oral NEPA is more effective in preventing CINV in acute, delayed, overall phases in patients receiving high dose chemotherapy as conditioning regimen for Auto-SCT. Fos APR may increase the risk for ISR associated with TC
- ||| netupitant (Ro 67-3189) / Helsinn, Otsuka
Journal, Adverse events, Real-world evidence, Real-world: Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database. (Pubmed Central) - Aug 15, 2024
In addition to paying attention to common AEs, clinicians need to pay attention to new emerging AEs, such as joint deposit, seizure-like phenomena, neutropenic colitis, colitis, and stomatitis, regarding the three NK-1RA drugs. Furthermore, the AE compositions of the three NK-1RA drugs were different in different genders, and clinicians should take these factors into account when selecting NK-1RAs for CINV treatment.
- HR20013 / Jiangsu Hengrui Pharma
Phase 3 Study of HR20013 For Prevention of Cisplatin-based Chemotherapy-induced Nausea and Vomiting (PROFIT Study) (30BC) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_879;
P3
The study (NCT05509634) aimed to assess HR20013 versus fosaprepitant (FAPR) plus PALO (FAPR+PALO) regimen in preventing cisplatin-based HEC-CINV...All pts also received oral dexamethasone (DEX) on days 1-4...CR Cycle 1 Cycle 2 HR20013+DEX (N=373) FAPR+PALO+DEX (N=377) D P HR20013+DEX (N=314) FAPR+PALO+DEX (N=336) D P OP 290 (77.7) 295 (78.2) -0.9 (-6.7, 5.0) <0.01 * 254 (80.9) 263 (78.3) 2.4 (-3.7, 8.5) 0.44 AP 340 (91.2) 339 (89.9) 1.0 (-3.2, 5.2) 0.64 293 (93.3) 306 (91.1) 2.2 (-1.9, 6.2) 0.30 DP 298 (79.9) 304 (80.6) -1.2 (-6.8, 4.4) 0.68 255 (81.2) 267 (79.5) 1.5 (-4.5, 7.6) 0.62 BDP 337 (90.3) 326 (86.5) 3.7 (-0.9, 8.2) 0.11 291 (92.7) 295 (87.8) 4.8 (0.3, 9.2) 0.04 0-168 h 285 (76.4) 283 (75.1) 1.0 (-5.1, 7.0) 0.75 250 (79.6) 256 (76.2) 3.2 (-3.0, 9.5) 0.32 Data are n (%) or % (95% CI). * Only P for primary endpoint was 1-sided for the noninferiority test.
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: A randomized, controlled, multicenter, phase II clinical trial of the combination of Fosapitam with chemotherapy and bevacizumab in the second-line treatment of advanced colorectal cancer (EUDRACT) - Jul 15, 2024
P2, N=82, Not yet recruiting, Sponsor: The 903rd Hospital of the Joint Logistics Support Force of the People's Liberation Army of China; The 903rd Hospital of the Joint Logistics Support Fo
- | carboplatin / Generic mfg., olanzapine / Generic mfg., paclitaxel / Generic mfg.
Trial termination: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients (clinicaltrials.gov) - Jun 9, 2024
P3, N=62, Terminated, Sponsor: University of Michigan Rogel Cancer Center
* Only P for primary endpoint was 1-sided for the noninferiority test. Active, not recruiting --> Terminated; Lack of Patient Population
- || cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Clinical, Journal, CINV: Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting. (Pubmed Central) - Jun 5, 2024
Active, not recruiting --> Terminated; Lack of Patient Population The administration of two-dose fosaprepitant was safe and more effective than one dose in protecting patients from CINV induced by three-day cisplatin included chemotherapy.
- | New trial, Surgery, Machine learning: A Machine Learning Prediction Model for Delayed CIPONV (clinicaltrials.gov) - Jun 5, 2024
P=N/A, N=1154, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- || fosaprepitant / Generic mfg.
New P1 trial: An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects (clinicaltrials.gov) - May 23, 2024
P1, N=40, Not yet recruiting, Sponsor: Zhuhai Beihai Biotech Co., Ltd
- | fosaprepitant / Generic mfg.
Trial completion date: Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov) - May 19, 2024
P2/3, N=250, Not yet recruiting, Sponsor: Montefiore Medical Center
The administration of two-dose fosaprepitant was safe and more effective than one dose in protecting patients from CINV induced by three-day cisplatin included chemotherapy. Trial completion date: May 2025 --> Dec 2024
- fosaprepitant / Generic mfg.
Cost-effectiveness of single-day intravenous fosaprepitant versus three-day oral aprepitant anti-emetic regimen in pediatric patients receiving highly-emetogenic chemotherapy. (Hall A; Poster Bd #: 442) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3445;
Fosaprepitant was not found to be cost-effective versus aprepitant in India, comparatively it was cost-saving and cost-effective in the US. These findings highlight the necessity of region-specific considerations when evaluating the cost-effectiveness of anti-emetic regimens.
- | fosaprepitant / Generic mfg.
New P2/3 trial: Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov) - Apr 23, 2024
P2/3, N=250, Not yet recruiting, Sponsor: Montefiore Medical Center
- | cisplatin / Generic mfg.
Retrospective data, Journal, Real-world evidence, CINV, Real-world: Retrospective analysis of real-world prescribing data for managing cisplatin-based chemotherapy-induced nausea and vomiting in China. (Pubmed Central) - Mar 26, 2024
The current study reveals suboptimal utilization of recommended antiemetic drugs for managing cisplatin-based HEC-induced nausea and vomiting in China. Improving the management of CINV is crucial, and these findings provide valuable insights into optimizing antiemetic drug practices.
- || cisplatin / Generic mfg., fosaprepitant / Generic mfg.
Review, Journal: Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature. (Pubmed Central) - Mar 18, 2024
The use of fosaprepitant in preventing CINV reduced incidence of moderate to severe nausea and vomiting. No correlation has been found between nausea and median dose to DVC and AP.
- | ondansetron / Generic mfg.
New P3 trial: the Efficacy and Safety of Ondansetron Oral Soluble Pellicles (clinicaltrials.gov) - Feb 28, 2024
P3, N=184, Recruiting, Sponsor: The First Affiliated Hospital of Xinxiang Medical College
- | carboplatin / Generic mfg., olanzapine / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Enrollment change: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients (clinicaltrials.gov) - Feb 28, 2024
P3, N=62, Active, not recruiting, Sponsor: University of Michigan Rogel Cancer Center
No correlation has been found between nausea and median dose to DVC and AP. Recruiting --> Active, not recruiting | N=170 --> 62
- || fosaprepitant / Generic mfg.
Retrospective data, Review, Journal: Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single-center review. (Pubmed Central) - Feb 26, 2024
In this retrospective, single-center study, 106 pediatric patients received either fosaprepitant or intravenous aprepitant as part of their antiemetic regimen. Intravenous aprepitant was well tolerated and did not lead to any instances of hypersensitivity reactions requiring discontinuation.
- | Trial completion, Trial completion date, Trial primary completion date: HELEN-009: Anti-emetic Prophylaxis With or Without Dexamethasone (clinicaltrials.gov) - Feb 26, 2024
P3, N=403, Completed, Sponsor: Henan Cancer Hospital
Intravenous aprepitant was well tolerated and did not lead to any instances of hypersensitivity reactions requiring discontinuation. Recruiting --> Completed | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jan 2024 --> Aug 2023
- | voriconazole / Generic mfg.
Journal: Mechanism Underlying Conflicting Drug-Drug Interaction Between Aprepitant and Voriconazole via Cytochrome P450 3A4-Mediated Metabolism. (Pubmed Central) - Feb 19, 2024
These results indicate that aprepitant initially inhibited voriconazole metabolism via its triazole ring and increased cytochrome P450 3A4 induction following L-755446 formation. The decrease in plasma voriconazole concentration 7 days after fosaprepitant administration was mainly attributed to cytochrome P450 3A4 induction by L-755446.
- ||| fosaprepitant / Generic mfg.
P3 data, Journal, CINV: Comparison of oral aprepitant and intravenous fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric oncology patients: a randomized phase III trial. (Pubmed Central) - Feb 7, 2024
P3
This study confirms the safety, efficacy, and potential advantages of fosaprepitant in reducing CINV in pediatric oncology patients. ClinicalTrials.gov identifier: NCT04873284.
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer (clinicaltrials.gov) - Feb 5, 2024
P3, N=116, Completed, Sponsor: Shantou University Medical College
ClinicalTrials.gov identifier: NCT04873284. Recruiting --> Completed | N=206 --> 116 | Trial completion date: Sep 2024 --> Aug 2023 | Trial primary completion date: Jul 2024 --> Jul 2023
- ||| dexamethasone / Generic mfg., fosaprepitant / Generic mfg., olanzapine / Generic mfg.
P3 data, Journal, CINV: Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study). (Pubmed Central) - Jan 22, 2024
Recruiting --> Completed | N=206 --> 116 | Trial completion date: Sep 2024 --> Aug 2023 | Trial primary completion date: Jul 2024 --> Jul 2023 This study shows that a DEX-free OPF regimen is efficacious and should be considered a standard option for acute and delayed CINV prophylaxis for HEC.
- | olanzapine / Generic mfg.
New P3 trial: Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov) - Jan 11, 2024
P3, N=370, Recruiting, Sponsor: Jiuda Zhao
- | fosaprepitant / Generic mfg.
Trial completion, Trial primary completion date: Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients (clinicaltrials.gov) - Jan 8, 2024
P2, N=108, Completed, Sponsor: Sun Yat-sen University
This study shows that a DEX-free OPF regimen is efficacious and should be considered a standard option for acute and delayed CINV prophylaxis for HEC. Not yet recruiting --> Completed | Trial primary completion date: Oct 2022 --> Jun 2023
- || fosaprepitant / Generic mfg., docetaxel / Generic mfg.
Review, Journal: Polysorbate 80 as a possible allergenic component in cross-allergy to docetaxel and fosaprepitant: A literature review. (Pubmed Central) - Nov 30, 2023
Most allergic reactions are not serious. Medications containing the same allergy ingredient need to be used with caution for patients with severe allergies to polysorbate 80.
- | Arokaris (fosnetupitant) / Helsinn, Otsuka, netupitant (Ro 67-3189) / Helsinn, Otsuka
Retrospective data, Clinical Trial,Phase III, Journal: Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase. (Pubmed Central) - Nov 27, 2023
Medications containing the same allergy ingredient need to be used with caution for patients with severe allergies to polysorbate 80. This analysis revealed that fosnetupitant could have long-acting antiemetic potency (>?120 h) and indicated the importance of antiemetic therapy at 0-120 h for CINV up to 168 h after chemotherapy.
- | fosaprepitant / Generic mfg.
Journal: Use of Fosaprepitant for Management of Suspected Antimicrobial-Associated Nausea: A Case Report. (Pubmed Central) - Nov 20, 2023
Its use in other contexts has not been well established. This case suggests a role for fosaprepitant in the management of nausea outside the context of chemotherapy or general anesthesia.
- | dexamethasone / Generic mfg., carboplatin / Generic mfg., fosaprepitant / Generic mfg.
Enrollment change, Trial termination: Low Dose Aprepitant for Patients Receiving Carboplatin (clinicaltrials.gov) - Nov 13, 2023
P2, N=15, Terminated, Sponsor: Albert Einstein College of Medicine
This case suggests a role for fosaprepitant in the management of nausea outside the context of chemotherapy or general anesthesia. N=50 --> 15 | Suspended --> Terminated; Expired IRB approval on 2/11/21
- Varubi (rolapitant oral) / TerSera Therap, GSK, netupitant (Ro 67-3189) / Helsinn, Otsuka
Prophylactic Neurokinin-1 Receptor Antagonist Use Pre- and Post- Choosing Wisely Initiative among Women with Breast Cancer (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1865;
Continued statewide or local educational efforts for dissemination of CW recommendations are needed to facilitate appropriate prophylactic use of NK1-RAs. Adjusted* Interrupted Time Series Segmented Regression Analysis of Prophylactic NK1-RA use among women with breast cancer before and after the Choosing Wisely initiative *Adjusted for insurance, health plan type, age, comorbidity, and emetic risk
- fosaprepitant / Generic mfg.
Dexamethasone is necessary for preventing acute emesis induced by anthracycline/cyclophosphamide chemotherapy(HELEN-009): a multicenter, randomized, open-labeled phase 3 trial (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1350;
P3
Proportion of patients in the efficacy analysis set achieving a complete response Treatment-related adverse events with an incidence ? 2%
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Doublet or triplet antiemetic prophylaxis for trastuzumab deruxtecan-induced nausea and vomiting: An open-label, randomized, multicenter, exploratory phase 2 study (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_566;
Breast cancer patients receiving T-DXd require triple therapy, including mandatory NK1RA administration, for antiemetic prophylaxis. Further investigation is needed to explore the development of more appropriate combination therapies for T-DXd-induced nausea and vomiting.